sellModerate cluster of 210b5-1 plan
Michel Detheux sold $1.6M of ITOS
Chief Executive Officer at iTeos Therapeutics, Inc.. 156,847 shares at an average of $10.15, traded Jun 4, 2025, filed Jun 6, 2025.
Warning score
43Value
$1.6M
156,847 shares
Holdings after
0
-109% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +25Trade size$1.6M at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-083411, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 4, 2025 | MOption exercise Common Stock10b5-1 | +8,400 | $4.30 | $36k | 144,303 | Jun 6, 2025 |
| Jun 4, 2025 | SOpen-market sale Common Stock10b5-1 | -8,400 | $10.10 | $85k | 135,903 | Jun 6, 2025 |
| Jun 4, 2025 | MOption exercise Common Stockindirect: By MG3A10b5-1 | +43,883 | $4.30 | $189k | 43,883 | Jun 6, 2025 |
| Jun 4, 2025 | SOpen-market sale Common Stockindirect: By MG3A10b5-1 | -43,883 | $10.10 | $443k | 0 | Jun 6, 2025 |
| Jun 5, 2025 | MOption exercise Common Stock10b5-1 | +8,400 | $4.30 | $36k | 144,303 | Jun 6, 2025 |
| Jun 5, 2025 | SOpen-market sale Common Stock10b5-1 | -8,400 | $10.15 | $85k | 135,903 | Jun 6, 2025 |
| Jun 5, 2025 | MOption exercise Common Stockindirect: By MG3A10b5-1 | +43,882 | $4.30 | $189k | 43,882 | Jun 6, 2025 |
| Jun 5, 2025 | SOpen-market sale Common Stockindirect: By MG3A10b5-1 | -43,882 | $10.15 | $445k | 0 | Jun 6, 2025 |
| Jun 6, 2025 | MOption exercise Common Stock10b5-1 | +8,400 | $4.30 | $36k | 144,303 | Jun 6, 2025 |
| Jun 6, 2025 | SOpen-market sale Common Stock10b5-1 | -8,400 | $10.21 | $86k | 135,903 | Jun 6, 2025 |
| Jun 6, 2025 | MOption exercise Common Stockindirect: By MG3A10b5-1 | +43,882 | $4.30 | $189k | 43,882 | Jun 6, 2025 |
| Jun 6, 2025 | SOpen-market sale Common Stockindirect: By MG3A10b5-1 | -43,882 | $10.21 | $448k | 0 | Jun 6, 2025 |
| Jun 4, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,400 | $0.00 | $0 | 51,600 | Jun 6, 2025 |
| Jun 4, 2025 | MOption exercise Stock Option (Right to Buy)derivativeindirect: By MG3A10b5-1 | -43,883 | $0.00 | $0 | 269,559 | Jun 6, 2025 |
| Jun 5, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,400 | $0.00 | $0 | 43,200 | Jun 6, 2025 |
| Jun 5, 2025 | MOption exercise Stock Option (Right to Buy)derivativeindirect: By MG3A10b5-1 | -43,882 | $0.00 | $0 | 225,677 | Jun 6, 2025 |
| Jun 6, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,400 | $0.00 | $0 | 34,800 | Jun 6, 2025 |
| Jun 6, 2025 | MOption exercise Stock Option (Right to Buy)derivativeindirect: By MG3A10b5-1 | -43,882 | $0.00 | $0 | 181,795 | Jun 6, 2025 |
Related signals
Other insiders at iTeos Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | iTeos Therapeutics, Inc. | Michel Detheux Chief Executive Officer | $1.0M 104,565 shares | -72% | |
| 33Weak | iTeos Therapeutics, Inc. | David Hallal director | $1.2M 114,682 shares | -300% | |
| 42Moderate | ITOSbuy iTeos Therapeutics, Inc. | EcoR1 Capital, LLC owner | $39M 4,958,978 shares | +87% | |
| 53Moderate | iTeos Therapeutics, Inc. | MPM BioVentures 2014, L.P. other | $5.1M 630,191 shares | -23% | |
| 53Moderate | iTeos Therapeutics, Inc. | Ansbert Gadicke other | $8.3M 1,031,931 shares | -23% | |
| 53Moderate | iTeos Therapeutics, Inc. | Mpm Bioventures 2018, L.p. other | $5.1M 630,191 shares | -23% | |
| 31Weak | ITOSbuy iTeos Therapeutics, Inc. | Matthew Gall Chief Financial Officer | $39k 5,000 shares | +8% | |
| 34Weak | ITOSbuy iTeos Therapeutics, Inc. | Matthew Gall Chief Financial Officer | $42k 5,000 shares | +35% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.